Breast Cancer Recurrence Risk Calculator

About This Risk Assessment

This calculator provides an individualized estimate of breast cancer recurrence risk based on established clinical and pathological factors. It is designed for patients who have completed primary treatment for early-stage breast cancer and want to understand their statistical risk profile over a defined time horizon. The tool synthesizes multiple prognostic variables into a single percentage estimate, helping inform surveillance planning and follow-up care discussions.

How Recurrence Risk Is Estimated

The calculation uses a validated statistical model that weighs the following clinical factors:

• Tumor size – Larger tumors generally carry a higher recurrence risk.
• Lymph node status – The number of positive lymph nodes is one of the strongest predictors of recurrence.
• Tumor grade – Higher grade (less differentiated) tumors tend to be more aggressive.
• Hormone receptor status – ER/PR positive tumors often have a lower recurrence risk, especially with endocrine therapy.
• HER2 status – HER2-positive tumors have distinct recurrence patterns, now modified by targeted therapies.
• Age at diagnosis – Younger age is associated with a slightly higher risk of recurrence in some subtypes.
• Treatment received – The model accounts for whether chemotherapy, endocrine therapy, or anti-HER2 therapy was administered.

The model assumes standard-of-care treatment was completed. It does not account for all possible biological subtypes or rare tumor characteristics.

How to Use the Calculator

1. Enter the patient's age at the time of initial diagnosis.
2. Select the tumor size in centimeters (or the closest approximation from the pathology report).
3. Indicate the number of positive lymph nodes found during surgery or biopsy.
4. Choose the tumor grade (1, 2, or 3) as reported in the pathology report.
5. Select hormone receptor status (ER/PR positive or negative).
6. Select HER2 status (positive or negative).
7. Indicate whether chemotherapy, endocrine therapy, and/or anti-HER2 therapy were received.
8. Click "Calculate" to see the estimated recurrence risk percentage.

Understanding Your Result

The result is expressed as a percentage representing the estimated likelihood of breast cancer recurrence (local, regional, or distant) within a specified time frame, typically 5 or 10 years. A lower percentage indicates a lower estimated risk; a higher percentage suggests a greater statistical chance of recurrence.

This estimate is a population-based projection, not a guarantee. Individual outcomes vary. The result should be interpreted as one piece of information within a broader clinical picture, not as a definitive prediction.

Common Misconceptions

• A low risk percentage does not mean zero risk. Even with favorable factors, recurrence remains possible.
• A high risk percentage does not mean recurrence is certain. Many patients with elevated risk estimates never experience recurrence.
• The estimate does not predict where recurrence might occur. It covers local, regional, and distant recurrence collectively.
• The model assumes treatment was completed as intended. Incomplete or delayed treatment may alter actual risk.

Limitations

• The model is based on data from specific patient populations and may not generalize perfectly to all ethnicities, age groups, or rare subtypes.
• It does not account for genomic assay results (e.g., Oncotype DX, MammaPrint) which can further refine risk for certain patients.
• Lifestyle factors, comorbidities, and adherence to long-term endocrine therapy are not included in the model.
• The calculator is intended for early-stage invasive breast cancer only. It is not validated for DCIS, inflammatory breast cancer, or metastatic disease at diagnosis.

Practical Use Cases

• Post-treatment counseling – Patients and clinicians can use the estimate to guide follow-up imaging schedules and surveillance intensity.
• Treatment decision support – The risk estimate may inform discussions about extended endocrine therapy or additional preventive measures.
• Patient education – Understanding personal risk can help patients engage more actively in their survivorship care plan.
• Research context – The tool can be used for educational purposes to illustrate how multiple factors combine to influence recurrence risk.